ZA200209808B - Protease inhibitors. - Google Patents
Protease inhibitors. Download PDFInfo
- Publication number
- ZA200209808B ZA200209808B ZA200209808A ZA200209808A ZA200209808B ZA 200209808 B ZA200209808 B ZA 200209808B ZA 200209808 A ZA200209808 A ZA 200209808A ZA 200209808 A ZA200209808 A ZA 200209808A ZA 200209808 B ZA200209808 B ZA 200209808B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- azepan
- butyl
- amide
- carboxylic acid
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title description 7
- -1 piperidinyl-ethyl Chemical group 0.000 claims description 170
- 150000001875 compounds Chemical class 0.000 claims description 69
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 31
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 108090000625 Cathepsin K Proteins 0.000 claims description 16
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 13
- 125000002541 furyl group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 102000012479 Serine Proteases Human genes 0.000 claims description 7
- 108010022999 Serine Proteases Proteins 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001972 isopentyl group Chemical class [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 125000005605 benzo group Chemical group 0.000 claims description 5
- 125000000484 butyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 201000001245 periodontitis Diseases 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 206010065687 Bone loss Diseases 0.000 claims description 3
- 241000222716 Crithidia Species 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000001436 propyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 201000004409 schistosomiasis Diseases 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 241000233872 Pneumocystis carinii Species 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 claims 38
- YMZTUCZCQMQFMK-UHFFFAOYSA-N 3-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(C)=C(C(O)=O)OC2=C1 YMZTUCZCQMQFMK-UHFFFAOYSA-N 0.000 claims 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 6
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 230000001590 oxidative effect Effects 0.000 claims 3
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 claims 3
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims 3
- IPPUBOMFHJXYTO-UHFFFAOYSA-N 3-methyl-n-[1-[(3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl)carbamoyl]cyclopentyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(C)=C1C(=O)NC1(C(=O)NC2C(CN(CCC2)S(=O)(=O)C=2N=CC=CC=2)=O)CCCC1 IPPUBOMFHJXYTO-UHFFFAOYSA-N 0.000 claims 2
- UOJBPVNHCNJBSQ-UHFFFAOYSA-N 4-methylfuran-2-carboxylic acid Chemical compound CC1=COC(C(O)=O)=C1 UOJBPVNHCNJBSQ-UHFFFAOYSA-N 0.000 claims 2
- VCNGNQLPFHVODE-UHFFFAOYSA-N 5-methylthiophene-2-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)S1 VCNGNQLPFHVODE-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- VHRCHODSRLMXFM-UHFFFAOYSA-N furo[3,2-b]pyridine-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=N1 VHRCHODSRLMXFM-UHFFFAOYSA-N 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims 2
- GVZXSZWCZGKLRS-UHFFFAOYSA-N thieno[3,2-b]thiophene-5-carboxylic acid Chemical compound S1C=CC2=C1C=C(C(=O)O)S2 GVZXSZWCZGKLRS-UHFFFAOYSA-N 0.000 claims 2
- JBVXXGSEMNXAMH-LSLKUGRBSA-N (2s)-2-amino-4-methyl-n-(3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl)pentanamide Chemical compound C1C(=O)C(NC(=O)[C@@H](N)CC(C)C)CCCN1S(=O)(=O)C1=CC=CC=N1 JBVXXGSEMNXAMH-LSLKUGRBSA-N 0.000 claims 1
- RTQPRZHWZAYSQF-UHFFFAOYSA-N 1-methylbenzo[e][1]benzofuran-2-carboxylic acid Chemical compound C1=CC=CC2=C3C(C)=C(C(O)=O)OC3=CC=C21 RTQPRZHWZAYSQF-UHFFFAOYSA-N 0.000 claims 1
- VTUMIXJWXJGPJW-UHFFFAOYSA-N 2,5-dimethyl-3h-furan-2-carboxylic acid Chemical compound CC1=CCC(C)(C(O)=O)O1 VTUMIXJWXJGPJW-UHFFFAOYSA-N 0.000 claims 1
- CITKJMOBBHFQBZ-UHFFFAOYSA-N 3,5-dimethyl-1-benzofuran-2-carboxylic acid Chemical compound C1=C(C)C=C2C(C)=C(C(O)=O)OC2=C1 CITKJMOBBHFQBZ-UHFFFAOYSA-N 0.000 claims 1
- PSJMNAIMOCVKGC-UHFFFAOYSA-N 3-ethyl-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(CC)=C(C(O)=O)OC2=C1 PSJMNAIMOCVKGC-UHFFFAOYSA-N 0.000 claims 1
- CNUBKCREEQZXNE-UHFFFAOYSA-N 3-methylfuro[3,2-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2C(C)=C(C(O)=O)OC2=C1 CNUBKCREEQZXNE-UHFFFAOYSA-N 0.000 claims 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 claims 1
- RSQVGWNXFQXJPU-KEKNWZKVSA-N 4-[[(2s)-2-(1-benzothiophene-2-carbonylamino)-4-methylpentanoyl]amino]-n-(2-fluorophenyl)-3-oxoazepane-1-carboxamide Chemical compound O=C([C@@H](NC(=O)C=1SC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1C(=O)NC1=CC=CC=C1F RSQVGWNXFQXJPU-KEKNWZKVSA-N 0.000 claims 1
- SWAWPNJHQWZNQI-LBAQZLPGSA-N 4-[[(2s)-2-[(2,4-dimethylfuran-3-carbonyl)amino]-4-methylpentanoyl]amino]-n-(2-fluorophenyl)-3-oxoazepane-1-carboxamide Chemical compound N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)C(=O)NC=1C(=CC=CC=1)F)=O)C(=O)C=1C(C)=COC=1C SWAWPNJHQWZNQI-LBAQZLPGSA-N 0.000 claims 1
- MBJKFAUPYMUFOV-UHFFFAOYSA-N 4-methoxy-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound COC1=CC=CC2=C1C(C)=C(C(O)=O)O2 MBJKFAUPYMUFOV-UHFFFAOYSA-N 0.000 claims 1
- ADRFTNFHVKVATK-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CC=CC(C(F)(F)F)=C1 ADRFTNFHVKVATK-UHFFFAOYSA-N 0.000 claims 1
- HITUZQPFDWNUHA-UHFFFAOYSA-N 5-fluoro-1-benzofuran-2-carboxylic acid Chemical compound FC1=CC=C2OC(C(=O)O)=CC2=C1 HITUZQPFDWNUHA-UHFFFAOYSA-N 0.000 claims 1
- GMIDGDXRCTUPNM-UHFFFAOYSA-N 5-fluoro-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=C(F)C=C2C(C)=C(C(O)=O)OC2=C1 GMIDGDXRCTUPNM-UHFFFAOYSA-N 0.000 claims 1
- BKOHXOOAJNTFCM-UHFFFAOYSA-N 5-methoxy-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound COC1=CC=C2OC(C(O)=O)=C(C)C2=C1 BKOHXOOAJNTFCM-UHFFFAOYSA-N 0.000 claims 1
- YERPPGGLEJUGSG-ANYOKISRSA-N 5-methoxy-n-[(2s)-4-methyl-1-oxo-1-[(3-oxo-1-propylsulfonylazepan-4-yl)amino]pentan-2-yl]-1-benzofuran-2-carboxamide Chemical compound O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC(OC)=CC=C2O1 YERPPGGLEJUGSG-ANYOKISRSA-N 0.000 claims 1
- TZAGITKJEGVENE-UHFFFAOYSA-N 6-fluoro-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound FC1=CC=C2C(C)=C(C(O)=O)OC2=C1 TZAGITKJEGVENE-UHFFFAOYSA-N 0.000 claims 1
- CQZZSFNTQLCLJF-UHFFFAOYSA-N 6-methoxy-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound COC1=CC=C2C(C)=C(C(O)=O)OC2=C1 CQZZSFNTQLCLJF-UHFFFAOYSA-N 0.000 claims 1
- 102000004171 Cathepsin K Human genes 0.000 claims 1
- XFRYRYWKWCMYSR-ANYOKISRSA-N N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)S(=O)(=O)C=1C=C(F)C=CC=1)=O)C(=O)C1=CC=C(C)S1 Chemical compound N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)S(=O)(=O)C=1C=C(F)C=CC=1)=O)C(=O)C1=CC=C(C)S1 XFRYRYWKWCMYSR-ANYOKISRSA-N 0.000 claims 1
- MCZWPVHRVBQFKP-ANYOKISRSA-N N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)S(=O)(=O)C=1C=C(F)C=CC=1)=O)C(=O)C=1OC=CC=1C Chemical compound N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)S(=O)(=O)C=1C=C(F)C=CC=1)=O)C(=O)C=1OC=CC=1C MCZWPVHRVBQFKP-ANYOKISRSA-N 0.000 claims 1
- LWKYKJNAEXDPHV-WCSIJFPASA-N O1C(CC)=CC=C1CN1CC(=O)C(NC(=O)[C@H](CC(C)C)NC(=O)C=2OC3=CC=CC=C3C=2)CCC1 Chemical compound O1C(CC)=CC=C1CN1CC(=O)C(NC(=O)[C@H](CC(C)C)NC(=O)C=2OC3=CC=CC=C3C=2)CCC1 LWKYKJNAEXDPHV-WCSIJFPASA-N 0.000 claims 1
- ZDLAZUMWVANWAH-WCSIJFPASA-N O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC(N=1)=CSC=1N1CCOCC1 Chemical compound O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC(N=1)=CSC=1N1CCOCC1 ZDLAZUMWVANWAH-WCSIJFPASA-N 0.000 claims 1
- MAUDXQVNYMLXKL-WCSIJFPASA-N O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC1=CC=CC(C)=N1 Chemical compound O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC1=CC=CC(C)=N1 MAUDXQVNYMLXKL-WCSIJFPASA-N 0.000 claims 1
- SDBLOCLJJZVHRX-WCSIJFPASA-N O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC1=CC=CC=C1F Chemical compound O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC1=CC=CC=C1F SDBLOCLJJZVHRX-WCSIJFPASA-N 0.000 claims 1
- KQUHJBWHAQHSSV-BBMPLOMVSA-N O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC1=CN=NN1C1=CC=CC=C1 Chemical compound O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1CC1=CN=NN1C1=CC=CC=C1 KQUHJBWHAQHSSV-BBMPLOMVSA-N 0.000 claims 1
- SGUIIXWUXMKPSC-LBAQZLPGSA-N O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC=C1S(C)(=O)=O Chemical compound O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC=C1S(C)(=O)=O SGUIIXWUXMKPSC-LBAQZLPGSA-N 0.000 claims 1
- PKLZPPHXTXDYKR-KEKNWZKVSA-N O=C([C@@H](NC(=O)C=1SC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC(F)=C1 Chemical compound O=C([C@@H](NC(=O)C=1SC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC(F)=C1 PKLZPPHXTXDYKR-KEKNWZKVSA-N 0.000 claims 1
- WWSBFMOFBPCAOB-WCSIJFPASA-N O=C([C@H](CC(C)C)NC(=O)C=1OC2=CC=C(C=C2C=1)OC)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC(F)=C1 Chemical compound O=C([C@H](CC(C)C)NC(=O)C=1OC2=CC=C(C=C2C=1)OC)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC(F)=C1 WWSBFMOFBPCAOB-WCSIJFPASA-N 0.000 claims 1
- MVVIVGVODGJWHX-WCSIJFPASA-N O=C1CN(C(=O)CCC(C)C)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)O1 Chemical compound O=C1CN(C(=O)CCC(C)C)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)O1 MVVIVGVODGJWHX-WCSIJFPASA-N 0.000 claims 1
- XKGONUKIAVRBFV-GGYWPGCISA-N O=C1CN(CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2O1 Chemical compound O=C1CN(CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2O1 XKGONUKIAVRBFV-GGYWPGCISA-N 0.000 claims 1
- BFXZHWSSTIFIAS-LOACHALJSA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C(S1)=CC2=C1C=CS2 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C(S1)=CC2=C1C=CS2 BFXZHWSSTIFIAS-LOACHALJSA-N 0.000 claims 1
- BLGNJDNLFDWJRL-LYKKTTPLSA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=C(C)C=CO1 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=C(C)C=CO1 BLGNJDNLFDWJRL-LYKKTTPLSA-N 0.000 claims 1
- STXNVUUKZBBZPR-GGYWPGCISA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC(OC)=CC=C2O1 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC(OC)=CC=C2O1 STXNVUUKZBBZPR-GGYWPGCISA-N 0.000 claims 1
- UFLYTDAXPVDMOI-ZVAWYAOSSA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2S1 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2S1 UFLYTDAXPVDMOI-ZVAWYAOSSA-N 0.000 claims 1
- CXVAXQAPERCPSM-QWAKEFERSA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=C(C=CC=C2)C2=N1 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=C(C=CC=C2)C2=N1 CXVAXQAPERCPSM-QWAKEFERSA-N 0.000 claims 1
- DPDPZNLEQMOJRN-LOACHALJSA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CS1 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CS1 DPDPZNLEQMOJRN-LOACHALJSA-N 0.000 claims 1
- ARAPIDADRRZDRE-GGYWPGCISA-N O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CN=C(C=CC=C2)C2=N1 Chemical compound O=C1CN(S(=O)(=O)CC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CN=C(C=CC=C2)C2=N1 ARAPIDADRRZDRE-GGYWPGCISA-N 0.000 claims 1
- MWZXXYXCBNNNPU-ANYOKISRSA-N O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=C(C)C2=CC=CC=C2O1 Chemical compound O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=C(C)C2=CC=CC=C2O1 MWZXXYXCBNNNPU-ANYOKISRSA-N 0.000 claims 1
- JAMQHFFPLDEUGP-DJNXLDHESA-N O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=C(C)C=CO1 Chemical compound O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=C(C)C=CO1 JAMQHFFPLDEUGP-DJNXLDHESA-N 0.000 claims 1
- TVJCBNUXMDDVQQ-GGYWPGCISA-N O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2O1 Chemical compound O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2O1 TVJCBNUXMDDVQQ-GGYWPGCISA-N 0.000 claims 1
- SVHRZAZATIQRAJ-GGYWPGCISA-N O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2S1 Chemical compound O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CC2=CC=CC=C2S1 SVHRZAZATIQRAJ-GGYWPGCISA-N 0.000 claims 1
- HOVAEIQQRBIZFS-ANYOKISRSA-N O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CN=C(C=CC=C2)C2=N1 Chemical compound O=C1CN(S(=O)(=O)CCC)CCCC1NC(=O)[C@H](CC(C)C)NC(=O)C1=CN=C(C=CC=C2)C2=N1 HOVAEIQQRBIZFS-ANYOKISRSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YQVJNEAWIRWWJY-WCSIJFPASA-N n-(2-fluorophenyl)-4-[[(2s)-2-[(5-methoxy-1-benzofuran-2-carbonyl)amino]-4-methylpentanoyl]amino]-3-oxoazepane-1-carboxamide Chemical compound O=C([C@H](CC(C)C)NC(=O)C=1OC2=CC=C(C=C2C=1)OC)NC(C(C1)=O)CCCN1C(=O)NC1=CC=CC=C1F YQVJNEAWIRWWJY-WCSIJFPASA-N 0.000 claims 1
- VZYLYBBFUCMXBN-WCSIJFPASA-N n-(2-fluorophenyl)-4-[[(2s)-4-methyl-2-[(3-methyl-1-benzofuran-2-carbonyl)amino]pentanoyl]amino]-3-oxoazepane-1-carboxamide Chemical compound O=C([C@@H](NC(=O)C1=C(C2=CC=CC=C2O1)C)CC(C)C)NC(C(C1)=O)CCCN1C(=O)NC1=CC=CC=C1F VZYLYBBFUCMXBN-WCSIJFPASA-N 0.000 claims 1
- WJDIKGLAURFBQH-ANYOKISRSA-N n-(2-fluorophenyl)-4-[[(2s)-4-methyl-2-[(4-methylthiophene-2-carbonyl)amino]pentanoyl]amino]-3-oxoazepane-1-carboxamide Chemical compound N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)C(=O)NC=1C(=CC=CC=1)F)=O)C(=O)C1=CC(C)=CS1 WJDIKGLAURFBQH-ANYOKISRSA-N 0.000 claims 1
- ZRWCTYYKOZFENZ-AMVUTOCUSA-N n-[(2s)-1-[[1-(3-cyclohexylpropanoyl)-3-oxoazepan-4-yl]amino]-4-methyl-1-oxopentan-2-yl]-5-[3-(trifluoromethyl)phenyl]furan-2-carboxamide Chemical compound N([C@@H](CC(C)C)C(=O)NC1C(CN(CCC1)C(=O)CCC1CCCCC1)=O)C(=O)C(O1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 ZRWCTYYKOZFENZ-AMVUTOCUSA-N 0.000 claims 1
- ANMDNYIGRGPFIG-GGYWPGCISA-N n-[(2s)-1-[[1-(3-fluorophenyl)sulfonyl-3-oxoazepan-4-yl]amino]-4-methyl-1-oxopentan-2-yl]thieno[3,2-b]thiophene-5-carboxamide Chemical compound O=C([C@@H](NC(=O)C=1SC=2C=CSC=2C=1)CC(C)C)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=CC(F)=C1 ANMDNYIGRGPFIG-GGYWPGCISA-N 0.000 claims 1
- RJUAVNQOQFVQLL-YNMFNDETSA-N n-[(2s)-1-[[1-[(2-fluorophenyl)carbamoyl]-3-oxoazepan-4-yl]amino]-4-methyl-1-oxopentan-2-yl]quinoline-2-carboxamide Chemical compound O=C([C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)CC(C)C)NC(C(C1)=O)CCCN1C(=O)NC1=CC=CC=C1F RJUAVNQOQFVQLL-YNMFNDETSA-N 0.000 claims 1
- WPNSSNNRULAJNF-WCSIJFPASA-N n-[(2s)-1-[[1-[(2-fluorophenyl)carbamoyl]-3-oxoazepan-4-yl]amino]-4-methyl-1-oxopentan-2-yl]quinoxaline-2-carboxamide Chemical compound O=C([C@@H](NC(=O)C=1N=C2C=CC=CC2=NC=1)CC(C)C)NC(C(C1)=O)CCCN1C(=O)NC1=CC=CC=C1F WPNSSNNRULAJNF-WCSIJFPASA-N 0.000 claims 1
- LCABTJVLYBIALE-WCSIJFPASA-N n-[(2s)-4-methyl-1-[[1-(4-methylsulfonylphenyl)sulfonyl-3-oxoazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide Chemical compound O=C([C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)NC(C(C1)=O)CCCN1S(=O)(=O)C1=CC=C(S(C)(=O)=O)C=C1 LCABTJVLYBIALE-WCSIJFPASA-N 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 125000001147 pentyl group Chemical class C(CCCC)* 0.000 claims 1
- UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 claims 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 102100024940 Cathepsin K Human genes 0.000 description 18
- 210000000988 bone and bone Anatomy 0.000 description 14
- 102000005600 Cathepsins Human genes 0.000 description 11
- 108010084457 Cathepsins Proteins 0.000 description 11
- 208000006386 Bone Resorption Diseases 0.000 description 10
- 230000024279 bone resorption Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 6
- 210000002997 osteoclast Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 125000005425 toluyl group Chemical group 0.000 description 6
- 108090000526 Papain Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 102200160920 rs35304565 Human genes 0.000 description 4
- QCBZCEKWIGTIMT-UHFFFAOYSA-N 1,3-bis(sulfanyl)propan-2-one Chemical class SCC(=O)CS QCBZCEKWIGTIMT-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000004849 alkoxymethyl group Chemical group 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- QTLLOLTVQMFWDZ-UHFFFAOYSA-N 4-aminoazepan-3-one Chemical compound NC1CCCNCC1=O QTLLOLTVQMFWDZ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101710177066 Cathepsin O Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000024693 gingival disease Diseases 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102200029256 rs121964925 Human genes 0.000 description 2
- 102220024375 rs201069984 Human genes 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZYJSTSMEUKNCEV-UHFFFAOYSA-N 3-diazo-1-diazonioprop-1-en-2-olate Chemical class [N-]=[N+]=CC(=O)C=[N+]=[N-] ZYJSTSMEUKNCEV-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 1
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102100036829 Probable peptidyl-tRNA hydrolase Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000003541 chondroclast Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108090000711 cruzipain Proteins 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical class SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 1
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59384500A | 2000-06-14 | 2000-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200209808B true ZA200209808B (en) | 2004-07-09 |
Family
ID=24376433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200209808A ZA200209808B (en) | 2000-06-14 | 2002-12-03 | Protease inhibitors. |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1307204A4 (sk) |
JP (1) | JP2004503502A (sk) |
KR (1) | KR20030008220A (sk) |
CN (1) | CN1444481A (sk) |
AP (1) | AP2002002671A0 (sk) |
AR (1) | AR032622A1 (sk) |
AU (1) | AU2001268407A1 (sk) |
BG (1) | BG107327A (sk) |
BR (1) | BR0111693A (sk) |
CA (1) | CA2412353A1 (sk) |
CZ (1) | CZ20024086A3 (sk) |
EA (1) | EA200300018A1 (sk) |
EC (1) | ECSP024388A (sk) |
HU (1) | HUP0301231A2 (sk) |
IL (1) | IL153421A0 (sk) |
MA (1) | MA25758A1 (sk) |
MX (1) | MXPA02012442A (sk) |
NO (1) | NO20025786L (sk) |
NZ (1) | NZ522965A (sk) |
OA (1) | OA12288A (sk) |
PE (1) | PE20011374A1 (sk) |
PL (1) | PL360508A1 (sk) |
SK (1) | SK17592002A3 (sk) |
WO (1) | WO2001095911A1 (sk) |
ZA (1) | ZA200209808B (sk) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003513926A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
JP2003513927A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
CZ20031403A3 (cs) * | 2000-11-22 | 2003-10-15 | Smithkline Beecham Corporation | Inhibitor proteasy |
US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
HU229431B1 (en) | 2001-02-20 | 2013-12-30 | Chugai Pharmaceutical Co Ltd | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
US20040157828A1 (en) * | 2001-05-17 | 2004-08-12 | Ren Xie | Protease inhibitors |
CA2533747C (en) * | 2003-08-01 | 2012-11-13 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
ES2309563T3 (es) | 2003-08-01 | 2008-12-16 | Chugai Seiyaku Kabushiki Kaisha | Compuestos de piperidina utiles como inhibidores de malonil coenzima a descarboxilasa. |
ATE407673T1 (de) | 2003-08-01 | 2008-09-15 | Chugai Pharmaceutical Co Ltd | Azol-verbindungen auf cyanoguanidin-basis als malonyl-coa decarboxylase-hemmer |
EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
CN103275070A (zh) * | 2013-05-10 | 2013-09-04 | 郑彪 | 调节单核细胞增殖的四环化合物及其应用 |
US9427441B2 (en) | 2014-02-19 | 2016-08-30 | Indiana University Research And Technology Corporation | Targeting primary cilia to treat glaucoma |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
CZ20012277A3 (cs) * | 1998-12-23 | 2001-11-14 | Smithkline Beecham Corporation | Inhibitory proteázy |
JP2003513926A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
JP2003513956A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
AU2001286983A1 (en) * | 2000-09-01 | 2002-03-13 | Smith Kline Beecham Corporation | Method of treatment |
CZ20031403A3 (cs) * | 2000-11-22 | 2003-10-15 | Smithkline Beecham Corporation | Inhibitor proteasy |
US20040157828A1 (en) * | 2001-05-17 | 2004-08-12 | Ren Xie | Protease inhibitors |
-
2001
- 2001-06-14 AU AU2001268407A patent/AU2001268407A1/en not_active Abandoned
- 2001-06-14 NZ NZ522965A patent/NZ522965A/en unknown
- 2001-06-14 IL IL15342101A patent/IL153421A0/xx unknown
- 2001-06-14 OA OA1200200377A patent/OA12288A/en unknown
- 2001-06-14 JP JP2002510089A patent/JP2004503502A/ja active Pending
- 2001-06-14 WO PCT/US2001/019062 patent/WO2001095911A1/en active IP Right Grant
- 2001-06-14 MX MXPA02012442A patent/MXPA02012442A/es unknown
- 2001-06-14 CA CA002412353A patent/CA2412353A1/en not_active Abandoned
- 2001-06-14 CZ CZ20024086A patent/CZ20024086A3/cs unknown
- 2001-06-14 PL PL36050801A patent/PL360508A1/xx not_active Application Discontinuation
- 2001-06-14 SK SK1759-2002A patent/SK17592002A3/sk not_active Application Discontinuation
- 2001-06-14 HU HU0301231A patent/HUP0301231A2/hu unknown
- 2001-06-14 EA EA200300018A patent/EA200300018A1/ru unknown
- 2001-06-14 CN CN01813500A patent/CN1444481A/zh active Pending
- 2001-06-14 EP EP01946344A patent/EP1307204A4/en not_active Withdrawn
- 2001-06-14 KR KR1020027017045A patent/KR20030008220A/ko not_active Application Discontinuation
- 2001-06-14 BR BR0111693-2A patent/BR0111693A/pt not_active IP Right Cessation
- 2001-06-14 AR ARP010102840A patent/AR032622A1/es not_active Application Discontinuation
- 2001-06-14 PE PE2001000566A patent/PE20011374A1/es not_active Application Discontinuation
- 2001-06-14 AP APAP/P/2002/002671A patent/AP2002002671A0/en unknown
-
2002
- 2002-11-28 BG BG107327A patent/BG107327A/bg unknown
- 2002-12-02 NO NO20025786A patent/NO20025786L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209808A patent/ZA200209808B/en unknown
- 2002-12-12 EC EC2002004388A patent/ECSP024388A/es unknown
- 2002-12-13 MA MA26952A patent/MA25758A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP1307204A1 (en) | 2003-05-07 |
PL360508A1 (en) | 2004-09-06 |
JP2004503502A (ja) | 2004-02-05 |
SK17592002A3 (sk) | 2003-05-02 |
AP2002002671A0 (en) | 2002-12-31 |
NZ522965A (en) | 2004-06-25 |
ECSP024388A (es) | 2003-02-06 |
EA200300018A1 (ru) | 2003-06-26 |
BR0111693A (pt) | 2004-04-06 |
AU2001268407A1 (en) | 2001-12-24 |
IL153421A0 (en) | 2003-07-06 |
PE20011374A1 (es) | 2002-04-07 |
MXPA02012442A (es) | 2003-04-25 |
CN1444481A (zh) | 2003-09-24 |
AR032622A1 (es) | 2003-11-19 |
WO2001095911A1 (en) | 2001-12-20 |
CA2412353A1 (en) | 2001-12-20 |
CZ20024086A3 (cs) | 2003-05-14 |
KR20030008220A (ko) | 2003-01-24 |
NO20025786L (no) | 2003-02-12 |
MA25758A1 (fr) | 2003-04-01 |
OA12288A (en) | 2003-12-12 |
NO20025786D0 (no) | 2002-12-02 |
BG107327A (bg) | 2003-07-31 |
EP1307204A4 (en) | 2004-06-02 |
HUP0301231A2 (hu) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001243441B2 (en) | Protease inhibitors | |
US20020147188A1 (en) | Protease inhibitors | |
AU2001243441A1 (en) | Protease inhibitors | |
ZA200209808B (en) | Protease inhibitors. | |
EP1320370A1 (en) | Method of treatment | |
US20030144175A1 (en) | Protease inhibitors | |
WO2003053331A2 (en) | Protease inhibitors | |
US20050256100A1 (en) | Protease inhibitors | |
ZA200104208B (en) | Protease inhibitors. | |
US7109233B2 (en) | Protease inhibitors | |
US20040038965A1 (en) | Protease inhibitors | |
US20050203084A1 (en) | Protease inhibitors | |
US20050256105A1 (en) | Protease inhibitors | |
EP1384713A1 (en) | 4-amino-azepan-3-one derivatives as protease inhibitors |